Table 14.10
De Novo Posttransplant Solid Malignancy, 1996 to 2005
Heart Recipients

	Year of Transplant									
	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005
Total # of Post-Tx Malignancies	522	492	422	313	258	196	121	74	35	6
Malignancies by Type										
Squamous/Basal Cell Carcinoma	330	315	251	188	132	119	63	47	19	5
Melanoma	9	22	14	17	7	7	4	5	5	-
Kaposi Sarcoma	3	1	3	1	-	1	-	-	-	-
Central Nervous System	1	1	3	4	2	-	-	-	-	-
Genito-Urinary (1)	67	42	52	37	38	28	16	10	6	-
Gastro-Intestinal (2)	24	15	12	9	17	4	6	5	-	-
Primary Hepatic Tumor	2	4	1	1	2	2	-	-	-	-
Metastatic Hepatic Tumor	8	2	4	2	4	-	4	-	-	-
Larynx/Bronchi/Lung	41	51	38	37	27	20	15	3	4	-
Breast/Thyroid	10	11	15	7	4	6	3	4	1	-
Leukemia	1	3	3	1	-	-	2	-	-	-
Sarcoma (3)	2	1	1	-	2	-	2	-	-	-
Other	24	20	20	7	19	8	6	-	-	1
Unknown	-	4	5	2	4	1	-	-	-	-
Malignancies by Type (%)										
Squamous/Basal Cell Carcinoma	63.2%	64.0%	59.5%	60.1%	51.2%	60.7%	52.1%	63.5%	54.3%	83.3%
Melanoma	1.7%	4.5%	3.3%	5.4%	2.7%	3.6%	3.3%	6.8%	14.3%	-
Kaposi Sarcoma	0.6%	0.2%	0.7%	0.3%	-	0.5%	-	-	-	-
Central Nervous System	0.2%	0.2%	0.7%	1.3%	0.8%	-	-	-	-	-
Genito-Urinary (1)	12.8%	8.5%	12.3%	11.8%	14.7%	14.3%	13.2%	13.5%	17.1%	-
Gastro-Intestinal (2)	4.6%	3.0%	2.8%	2.9%	6.6%	2.0%	5.0%	6.8%	-	-
Primary Hepatic Tumor	0.4%	0.8%	0.2%	0.3%	0.8%	1.0%	-	-	-	-
Metastatic Hepatic Tumor	1.5%	0.4%	0.9%	0.6%	1.6%	-	3.3%	-	-	-
Larynx/Bronchi/Lung	7.9%	10.4%	9.0%	11.8%	10.5%	10.2%	12.4%	4.1%	11.4%	-
Breast/Thyroid	1.9%	2.2%	3.6%	2.2%	1.6%	3.1%	2.5%	5.4%	2.9%	-
Leukemia	0.2%	0.6%	0.7%	0.3%	-	-	1.7%	-	-	-
Sarcoma (3)	0.4%	0.2%	0.2%	-	0.8%	-	1.7%	-	-	-
Other	4.6%	4.1%	4.7%	2.2%	7.4%	4.1%	5.0%	-	-	16.7%
Unknown	-	0.8%	1.2%	0.6%	1.6%	0.5%	-	-	-	-
Total # of Patients	338	305	275	216	186	138	94	58	32	5

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
(-) = None in category.
(1) Genito-Urinary: kidney, bladder, uterine cervix, uterine body, ovarian, vulva, testicular, prostate.
(2) Gastro-Intestinal: tongue, throat, esophagus, stomach, small intestine, colo-rectal, liver and biliary tract, pancreas.
(3) Sarcoma: fibrosarcoma, osteosarcoma, etc.
Recipient malignancy statistics are based on voluntary reporting to the OPTN.